If this were true, a space for using drugs that decrease the circulating amounts of FSH and LH, such as gonadotrophin-releasing hormone receptor antagonists (GnRH-R antagonists) may exist in postmenopausal women, with the potential to either decrease the development of BCs or to help in controlling cancer progression. This evidence concerns the gene GNRHR and cancer.